Efficacy of Peptide Receptor Radionuclide Therapy for Esthesioneuroblastoma


Introduction: Esthesioneuroblastoma (ENB) is a rare malignancy with limited therapeutic options when unresectable or metastatic. The overexpression of cell-surface somatostatin receptors in ENB is a potential molecular target making it amenable to peptide receptor radionuclide therapy (PRRT). High-level evidence supporting PRRT has been published for unresectable gastroenteropancreatic neuroendocrine tumours; however, data is limited for PRRT efficacy for ENB.

Aim(s): We report outcomes of seven patients across 2 referral centers who have received PRRT for recurring or metastatic ENB.

Materials and methods: Using PRRT databases at two European Neuroendocrine Tumour Society (ENETS) Centers of Excellence, case finding was undertaken for patients who underwent PRRT between 2004 and 2018 for recurrent/metastatic ENB that were deemed unsuitable for further conventional therapies. Response and survival were evaluated; response evaluations were performed utilizing a composite reference standard.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Kamel Hasan O

Authors: Kamel Hasan O, Ravi Kumar A, Kong G, Grozinsky-Glasberg S, Hicks R,

Keywords: esthesioneuroblastoma, peptide receptor radionuclide therapy, lutetium-177 dotatate,

To read the full abstract, please log into your ENETS Member account.